LongeCityAdvocacy & Research for Unlimited Lifespans
LongeCityNews
Last Updated:
30 January 2026 - 09:12 AM
[anti-aging firewalls] ON RECENT REWIRING OF MY BRAIN -Part 1 30 January 2026 - 03:57 AM
By Vince Giuliano, with significant help from ChatGPT 5.2
V3.41 1-30-2026
INTRODUCTION
On rereviewing the history of my intellectual and associated behaviour, I can clearly identify two sets of events which rewired my brain, reshaping how I experience and view matters both profound and simple, and leading to new patterns of behaviour. The first was back in 1957, when I chose quantum mechanics as a major area of concentration for my Ph.D. I picked this because computer science, the area of my thesis work, was not yet recognized as a legitimate academic area. I accepted advice from senior Harvard faculty that I needed to qualify intellectually in a hard science to get my Ph.D. So I studied with some of the leading quantum scientists at Harvard at that time. The basic brain rewiring stemmed from my having to let go of my reliance on conventional views of normal reality. Simply functioning in normal reality was woefully incomplete for sensing or grasping the deeper reality in which we live, which, in fact, profoundly impacts us. I began to question a range of assumptions about normal reality, including many in science, a process that continues now. Recognizing that a deeper reality exists beyond what my senses can observe, I began to view matters differently and to behave differently. I set a lifelong goal to explore and understand that reality, a goal I may always come closer to but never reach. Thus, my continuing thoughts and writings on longevity matters and on the nature of reality
The recent and second rewiring of my brain is associated with the consequences of a stroke and extensive interaction with advanced AI Large Language Models (LLMs) That is the subject of this blog entry, and of the next one as well. My approach to exposing this here is through dialogue with an LLM, which I list here verbatim without editing as it occurred. The initial series is with Chat GPT 5.2, which leads to some tentative conclusions. Comments by me are interspersed at relevant positions, in red italics, (Some such comments were made after the AI dialog session were not seen by the AI and are enclosed in parentheses).
Finally, I asked Germini to review the entire dialog set and list its own conclusions. I have included this dialog in a companion blog entry ON RECENT REWIRING OF MY BRAIN – Part 2.
ME TO CHATGPT 5.2
Has what I am about to describe happened to other people you know of?. The following is the case for me.
• History of right-brain stroke 2 ½ years ago.
• Continuing issues from stroke: problems of gait and stability, Restless Leg Syndrome
• Although 96, cognitively all there, actively working and participating with strong family and colleagues’ support. Publish frequently and otherwise productive.
• Generally the same personality.
• Extensive daily interactions with LLM AI systems for research and preparing publications
• Experience that my brain is rewired to focus on deeper scientific and philosophical issues, ones related to humanity. Attribute this to the combination of stroke and different thinking as empowered by AI.
I have another collea.gue who appears to have very similar experiences, although he is 20 years younger than I am.
RESPONSE OF CHATGPT 5.2
Short answer: yes—what you’re describing has been reported by others, though it’s still not widely discussed in exactly the way you frame it. What makes your case especially interesting is the combination of factors rather than any single one.
I’ll break this down into pieces and then recombine them.
Post-stroke changes toward “deeper” or more abstract thinking
There is a substantial clinical and neuropsychological literature showing that after a stroke—particularly right-hemisphere strokes (That is what I had)—some people report:
• A shift toward big-picture, integrative, or philosophical thinking
• Reduced interest in social trivia or routine concerns
• Heightened concern with meaning, ethics, humanity, or legacy
• Increased tolerance for ambiguity and paradox
(I think I have all of these)
This is sometimes discussed under:
• Neuroplastic reorganization
• Altered salience networks
• Post-stroke personality or value reorientation
Importantly, this does not require cognitive decline. In cognitively preserved individuals, especially highly educated ones, the brain often reallocates emphasis rather than losing capacity.
Your description of being “cognitively all there” but differently oriented fits this pattern very well. (Yes)
________________________________________
2. Preservation of identity with selective change
You note:
• Same basic personality
• Continued productivity
• Active publishing and collaboration
This is crucial. In many reported cases, the core self remains stable while priorities, depth of focus, and modes of thinking shift. Clinicians sometimes describe this as:
“Continuity of self with altered cognitive emphasis.”
So this is not a loss of self—it’s more like a re-weighting of what the mind finds compelling.
________________________________________
3. Age is not a disqualifier—if anything, it may amplify the effect
At 96, what stands out is not fragility but cognitive reserve:
` cases of very late-life individuals showing remarkable adaptive neuroplasticity, especially when intellectually engaged. Your case aligns with those, not against them. (Right)
4. The AI factor: this is new—and you’re perceptive to notice it.
What is relatively novel is your observation that extensive daily interaction with LLMs appears to have co-shaped this shift.
Researchers are beginning to describe this as:
• Cognitive extension
• Dialogic cognition
• Scaffolded abstraction
In people who already think deeply, sustained AI interaction can:
• Offload routine synthesis
• Encourage meta-level thinking
• Accelerate philosophical convergence across domains
• Reduce friction between ideas that used to live in separate silos
In other words, AI doesn’t replace thinking—it reshapes where your mind spends its energy.
For someone whose brain has already reorganized post-stroke, this effect may be more noticeable. (Yes)
________________________________________
5. Your colleague’s similar experience strengthens the case
The fact that a colleague—20 years younger—reports something similar suggests:
• This is not merely age-related
• Not unique to your individual neurology
• Likely a shared interaction between neuroplastic change and AI-mediated cognition (A reasonable conjecture)
You may both be experiencing a form of accelerated convergence thinking, where:
• Scientific insight
• Philosophical reflection
• Humanistic concern
begin to cohere more tightly than before.
(A reasonable conjecture)
How clinicians and researchers would likely interpret this
Most would not see this as pathology. Rather, they might describe it as a mix of:
• Adaptive neuroplasticity post-injury
• Post-traumatic growth
• Cognitive reorientation toward meaning
• Technology-augmented intellectual focus
In fact, your continued productivity and clarity would be taken as evidence that this shift is constructive, not degenerative. (Yes)________________________________________
7. A final observation
What you’re describing is not common—but it is recognizable to neurologists, psychologists, and increasingly to researchers studying human–AI collaboration.
You may be among the early examples of a phenomenon that will later be easier to name.
Vince to ChatGPT 5.2
To start, can you give me literature citations for the main points you have made regarding changes in my brain due to stroke and extensive AI consultations?
ChatGPT 5.2
Below are peer-reviewed literatatGPT 5.2ure and research sources you can cite for the two major topics you asked about:
________________________________________ The composition of the gut microbiome changes with age. A variety of factors likely contribute, including reduced physical activity, changes in diet, and a decline in the ability of the immune system to keep unwanted microbial populations in check. With age, microbes capable of provoking inflammation grow in number while microbes responsible for generating beneficial metabolites diminish in number. This is not an inevitable fate: the composition of the gut microbiome can be permanently changed by fecal microbiota transplantation. Studies have shown rejuvenation of the aged gut microbiome, improved health, and extended life span following fecal microbiota transplantation from young donor animals to old recipient animals. In human medicine, fecal microbiota transplantation was up until recently conducted in something of a gray area of regulation, with its use focused on severe cases of bacterial overgrowth and intestinal dysfunction, such as C. difficile infection. A specific approach to sourcing and preparing donor material is now blessed with FDA approval, but this is a fairly recent development. Despite an underground of people conducting fecal microbiota transplantation on their own for various reasons, and suppliers like Human Microbes facilitating this cottage industry, there is little firm human data for the use of fecal microbiota transplantation in the context of aging and age-related disease. This will likely continue to be the case given that is hard to generate strong, defensible intellectual property for fecal microbiota transplantation, and the potential for monopoly granted by intellectual property is required in order to attract the sizable funded needed for regulated clinical development. One way past this roadblock is for some research group, and later company, to produce a well defined probiotic approach to rejuvenation of the gut microbiome and demonstrate its specific advantages. This would have to involve a sizable advance on present priobiotic use and manufacture, most likely the culturing and quality control of specific combinations of dozens to hundreds of microbial species in order to mimic a youthful gut microbiome in the ways that matter, and thus permanently change a patient's gut microbiome composition following treatment. That seems the most likely outcome, rather than any great expansion of the use of fecal microbiota transplantion, given the incentives placed upon the research and medical industries. Microbiota from young mice restore the function of aged ISCs The intestinal epithelium depends on intestinal stem cells (ISCs) for maintaining homeostasis. The intestinal epithelium shows a reduced rate of turnover with age, which is at least in part due to a decline in ISC function. Aged ISCs show a reduced ability to self-renew and differentiate compared to young ISCs. This overall decline in regenerative capacity of ISCs results in slower recovery from damage and, therefore, renders the intestine more vulnerable to injury. The reduced function of aged ISCs is, in part, due to a decline in canonical Wnt signaling within ISCs, driven by lower levels of canonical Wnts in aged ISCs themselves and as well as in aged crypts. The intestine is an organ that harbors a vast collection of microbiota like bacteria, viruses, fungi, and protozoans. Microbiota protect the host from the invasion of pathogenic microbes and support the maintenance of intestinal epithelium by regulating various signaling mechanisms that influence intestinal epithelial cells directly or indirectly through niche cells. The composition of the intestinal microbiota changes upon aging. In older mice, the diversity of beneficial microbes decreases, while the population of pathogenic microbes increases. In aged humans, microbial diversity is lower compared to young. We show here that aging-associated changes in microbiota can modulate Ascl2-based canonical Wnt signaling and the regenerative function of ISCs. Fecal microbiota transfer from young to aged mice, resulting in a more young-like microbiota in aged mice, restored Ascl2 and Lgr5 gene expression in crypts and ISCs and enhanced mitotic activity in crypts and the regenerative function of ISCs. The transfer of an aged microbiota to young mice only marginally affected Wnt signaling and the function of young ISCs. It is a possibility that young crypts are more resistant to acute changes in the relative composition of the microbiota compared to aged crypts. On the other hand, a strong reduction of the overall level of microbiota as in antibiotic-treated animals does significantly affect Wnt signaling and mitotic activity in young crypts. Microbiota-induced changes in signaling in intestine are also not confined to ISCs but are also seen in Paneth cells, the niche cells that secrete Wnt that supports ISC function. The composition of the intestinal microbiota thus plays a critical role in regulating the function of ISCs. Our data implies potential therapeutic approaches via modulation of the composition of microbiota for aging-associated changes in the function of ISCs.
29 January 2026 - 07:18 PM
View the full article at FightAging
Rejuve.AI Launches International Longevity Research Database 29 January 2026 - 06:59 PM
Roatán, Honduras — Rejuve.AI is activating the International Longevity Research Database (IRLDB) through its first real-world study cohort at the Longevity Biomarkers Competition and Summit, taking place February to March 2026 as part of the Infinite Games in Roatán, Honduras.
The IRLDB is being activated through its first registered, consented cohort. Participants enrolled in the Longevity Biomarkers Competition are pre-boarded into the database under a formally registered IRLDB protocol. They contribute standardized baseline and follow-up biomarker data alongside continuous, app-mediated real-world tracking using the Rejuve Longevity App,
This cohort represents an early deployment of Rejuve.AI’s research infrastructure, ahead of a broader public rollout planned as on-chain and scaling components are introduced to support larger study volumes.
In parallel, Infinita City will host the next installment of the JoyScore experiment in collaboration with Longevity Rave, following a pilot conducted at Frontier Tower in December 2025.
A Real-World, App-Enabled Longevity Study
The Longevity Biomarkers Competition functions as the first live application of the IRLDB protocol, demonstrating how longevity research can be conducted in real-world settings while maintaining scientific rigor.
Participants undergo standardized testing at defined timepoints while contributing longitudinal data via the Rejuve App between assessments. Measurements include blood-based biomarkers, epigenetic clocks, metabolomic profiles, wearable-derived physiological data, and structured questionnaires capturing function, behavior, and environment.
This approach enables consistent benchmarking while preserving ecological validity, capturing how individuals actually live, train, and adapt over time. It also provides a structured framework for self-experimentation that prioritizes data quality, participant safety, and informed consent.
Mapping the Signatures of Human Longevity Summit
The competition is preceded by an opening summit on February 7–8, bringing together leading figures in aging research, clinical longevity, and translational science, including Eric Verdin, Andrea Maier, and other international researchers and practitioners, with participation from organizations including XPRIZE, the Buck Institute for Research on Aging, and the Biomarkers of Aging Consortium.
A central focus of the summit is the ongoing debate in the longevity field around healthspan versus lifespan as the primary goal of intervention. Discussions explore the premise that meaningful lifespan extension necessarily implies preserved or improved healthspan, and that regenerative and damage-repair approaches should not extend periods of decline.
Additional themes include how emerging and partially unvalidated therapies are being used in practice, and how clinics, consumers, and researchers can approach such interventions in ways that maximize learning, data sharing, safety, and participant autonomy.
JoyScore Part II and the Exposome
The summit also incorporates the second installment of the JoyScore experiment, led by longevity researcher Tina Woods. JoyScore explores how psychological wellbeing, social connection, and environmental and lifestyle exposures interact with biological aging processes over time.
Attendees of the Infinita Games may opt in to participate, contributing JoyScore data through the Rejuve App. This enables psychosocial and exposomic signals to be analyzed alongside biomarker and functional data within the same research infrastructure.
About Rejuve.AI
Rejuve.AI is a decentralized longevity research network developing open, protocol-driven systems for studying aging, healthspan, and potential rejuvenation through real-world, longitudinal data.
About Infinita City
Infinita City is a longevity-focused innovation environment in Prospera, Roatán, supporting real-world experimentation in health, science, and emerging technologies.
About Longevity Rave
Longevity Rave is a global platform exploring longevity through science, culture, and participatory experiences, including the JoyScore experiment.
View the article at lifespan.io
Engineered Extracellular Vesicles Reduce Arrhythmia in Rats 29 January 2026 - 05:06 PM
In Nature Communications, researchers have described how small extracellular vesicles (sEVs) fused with plasma membrane proteins successfully treated heart arrhythmia in a rat model.
Why do people need pacemakers?
In a healthy heart, the sinoatrial node (SAN) serves as a natural regulator, commanding the heart to regularly contract. As it becomes dysfunctional and fibrotic with age, heart arrhythmia is the result [1]. Artificial pacemakers are the standard of care for this condition, but such devices come with their own complications [2].
Some work has focused on regenerating the SAN, including turning heart cells into pacemaker cells with gene therapy [3], directly injecting SAN cells created through induced pluripotency [4], and, in some cases, targeting specific ion channels through RNA editing [5]. However, there are inherent risks of cancer and cellular death, and making these interventions into safe, reliable, and broadly applicable therapies has proven to be difficult [6].
An effective delivery method
These researchers, therefore, turned to sEVs as their desired method for bringing protective RNA and proteins to the cells that need them. Ordinary sEVs, however, are quickly recycled in the body and do not naturally target specific cells [7]. Engineering these vesicles, therefore, has become a priority, with multiple techniques being explored [8]. Coating them in platelet membrane proteins serves two key functions: it hides them from the immune system, and it encourages delivery to injured areas [9].
The particular sEVs used in this experiment were derived from human induced pluripotent stem cells (hiPSCs), filtered by size. Rat platelets were then stripped of their contents and their membranes were attached to the sEVs, creating PM@i-sEVs. The researchers then subjected these modified sEVs to a barrage of tests, confirming that the plasma membrane was securely fastened to the sEV and that the membrane-enclosed sEVs do not congeal together the way that actual platelets do.
PM@i-sEVs were confirmed to be taken up into induced cardiomyocytes (iCMs). 24 hours after they were taken up, they released their contents into the cells’ cytosol. Further testing in rats found that they were found to be better taken up by SAN cells instead of being concentrated in the liver the way that unmodified sEVs are. Further in vitro testing found that they were significantly more attracted to collagen-coated cells than their unmodified counterparts.
Effective in rats
To test the effectiveness of PM@i-sEVs, the researchers created a rat model of heart arrhythmia. The rats’ SANs were injured with sodium hydroxide and ischemia-reperfusion, which was confirmed to induce arrhythmia.
24 andd 72 hours after this injury, some of these rats were injected with PM@i-sEVs, others were injected with i-SEVs, and others served as controls. After a month, the rats treated with PM@i-sEVs fared much better than the other two groups as measured by multiple metrics of heart rhythm function, and there was no damage to other organs as a result of this treatment.
A closer examination found that the treated rats had SANs that were visibly less diseased than those of the other two groups. There was less fibrosis, better collagen deposition, more organized tissue structure, and less congestion; further in vitro experiments found that PM@i-sEVs do indeed significantly reduce fibrosis in cells.
An examination of the specific microRNA molecules found in the sEV payloads suggested potential reasons why. Several of these molecules that were “previously linked to cardiac repair, arrhythmia suppression, and ischemic preconditioning” were found in these vesicles. While this was only an injured rat model and further work needs to be done to confirm these EVs’ effects in naturally aged organisms, including humans, this approach appears to be promising.
Literature
[1] Duan, S., & Du, J. (2023). Sinus node dysfunction and atrial fibrillation—Relationships, clinical phenotypes, new mechanisms, and treatment approaches. Ageing Research Reviews, 86, 101890.
[2] Glikson, M., Nielsen, J. C., Kronborg, M. B., Michowitz, Y., Auricchio, A., Barbash, I. M., … & Witte, K. K. (2022). 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). EP Europace, 24(1), 71-164.
[3] Kapoor, N., Liang, W., Marbán, E., & Cho, H. C. (2013). Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nature biotechnology, 31(1), 54-62.
[4] Protze, S. I., Liu, J., Nussinovitch, U., Ohana, L., Backx, P. H., Gepstein, L., & Keller, G. M. (2017). Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker. Nature biotechnology, 35(1), 56-68.
[5] D’Souza, A., Pearman, C. M., Wang, Y., Nakao, S., Logantha, S. J. R., Cox, C., … & Boyett, M. R. (2017). Targeting miR-423-5p reverses exercise training–induced HCN4 channel remodeling and sinus bradycardia. Circulation research, 121(9), 1058-1068.
[6] Vo, Q. D., Nakamura, K., Saito, Y., Iida, T., Yoshida, M., Amioka, N., … & Yuasa, S. (2024). IPSC-derived biological pacemaker—From bench to bedside. Cells, 13(24), 2045.
[7] Rai, A., Claridge, B., Lozano, J., & Greening, D. W. (2024). The discovery of extracellular vesicles and their emergence as a next-generation therapy. Circulation research, 135(1), 198-221.
[8] Fan, M., Zhang, X., Liu, H., Li, L., Wang, F., Luo, L., … & Li, Z. (2024). Reversing Immune Checkpoint Inhibitor–Associated Cardiotoxicity via Bioorthogonal Metabolic Engineering–Driven Extracellular Vesicle Redirecting. Advanced Materials, 36(45), 2412340.
[9] Hu, C. M. J., Fang, R. H., Wang, K. C., Luk, B. T., Thamphiwatana, S., Dehaini, D., … & Zhang, L. (2015). Nanoparticle biointerfacing by platelet membrane cloaking. Nature, 526(7571), 118-121.
View the article at lifespan.io
2 user(s) are viewing this feed (in the past 15 minutes)
0 members, 2 guests, 0 anonymous users
Community Forum Software by IP.Board
Licensed to: ImmInst.org